Proactive Research analyst Emma Ulker says Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) is driving forwards at speed with the clinical development plan for its fully-human mAb TZLS-501 COVID-19 treatment. She adds that with GMP-grade manufacturing already underway they've appointed a number of CROs to develop and test the handheld nebuliser, to conduct an inhalation safety toxicity study and to initiate a human clinical trial in COVID-19 patients.
Tiziana Life Sciences PLC's clinical plan is shaping up says analyst Emma Ulker
Quick facts: Tiziana Life Sciences PLC
Price: 135 GBX
Market Cap: £258.07 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...FOR OUR FULL DISCLAIMER CLICK HERE